BOSTON SCIENTIFIC CORP BSX revenue by segment, product and geography
In its fiscal year ending 2025-12-31, BOSTON SCIENTIFIC CORP reported revenue across 6 geographies; the largest, United States, was $12.9B (+26.0% against the prior period in the same filing).
Reported segment mix
figures as filed · share of the filed sum · change vs the prior period in the same filing- United States$12.9Bshare n/a+26.0% yoy
- Outside the United States$7.21Bshare n/a+10.3% yoy
- EMEA$3.45Bshare n/a+6.9% yoy
- Asia Pacific$3.08Bshare n/a+14.7% yoy
- Emerging Markets$2.98Bshare n/a+11.4% yoy
- Latin Americaand Canada$678Mshare n/a+8.7% yoy
member sum exceeds the consolidated figure: this axis carries more than one breakdown, so shares are not computed.
- Cardiovascular$3.5B67.3%+13.5% yoy
- Medsurg$1.7B32.7%+7.9% yoy
Change is against the same quarter a year earlier, as reported in the same 10-Q.
Source: SEC DERA Financial Statement and Notes data sets. Dimensional XBRL facts on the business-segment, product/service and geographic axes; the engine keeps the accession of every figure. Descriptive and educational, not advice.
About these figures
Companies tag segment, product and geographic revenue as dimensional XBRL facts in their 10-K and 10-Q filings. The SEC publishes those facts in its DERA Financial Statement and Notes data sets; TrendNalysis ingests each monthly file and serves the facts exactly as filed, keyed to the accession of the filing. Shares are of the filed sum. Where a filer tags more than one breakdown on one axis, the sum exceeds consolidated revenue and no shares are computed; where the members do not add up to the consolidated figure, the residual is stated rather than hidden. Missing is never zero.
Descriptive and educational; not investment advice. Methodology and data lineage.